Atogepant (Qulipta) for Migraine Prevention

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2021年 / 63卷 / 1636期
关键词：
DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：169 / 171
页数：3
相关论文
共 50 条
  • [21] The preclinical discovery and development of atogepant for migraine prophylaxis
    Baraldi, Carlo
    Beier, Dagmar
    Martelletti, Paolo
    Pellesi, Lanfranco
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (07) : 783 - 788
  • [22] Atogepant, the first oral preventive treatment for chronic migraine
    Haanes, Kristian A.
    Edvinsson, Lars
    LANCET, 2023, 402 (10404): : 748 - 749
  • [23] Rimegepant versus atogepant and monoclonal antibody treatments for the prevention of migraine: A systematic literature review and network meta-analysis
    Popoff, E.
    Powell, L.
    Rahim, T.
    Johnston, K. M.
    Harris, L.
    Thiry, A. C.
    Coric, V
    L'Italien, G. J.
    HEADACHE, 2021, 61 : 145 - 146
  • [24] Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
    Popoff, E.
    Powell, L.
    Rahim, T.
    Johnston, K.
    Harris, L.
    Thiry, A.
    Coric, V.
    L'Italien, G.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 122 - 122
  • [25] Comparative Efficacy, Quality of Life, and Safety/Tolerability of Atogepant and Rimegepant in Migraine Prevention: A Matching-Adjusted Indirect Comparison
    Tassorelli, Cristina
    Onishchenko, Kateryna
    Duan, Molly
    Hemstock, Matthew
    Voller, Corey
    Gandhi, Pranav
    Dupont-Benjamin, Laure
    CEPHALALGIA, 2023, 43 (1supp) : 258 - 260
  • [26] Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
    Popoff, Evan
    Powell, Lauren
    Johnston, Karissa
    O'Sullivan, Fiona
    Harris, Linda
    Leroue, Chelsea
    Croop, Robert
    Coric, Vlad
    Moren, James
    NEUROLOGY, 2022, 98 (18)
  • [27] Comparative Efficacy, Quality of Life, and Safety/Tolerability of Atogepant and Rimegepant in Migraine Prevention: A Matching-Adjusted Indirect Comparison
    Tassorelli, C.
    Onishchenko, K.
    Duan, M.
    Hemstock, M.
    Voller, C.
    Gandhi, P.
    Dupont-Benjamin, L.
    HEADACHE, 2023, 63 : 122 - 123
  • [28] Rimegepant Versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
    Popoff, E.
    Powell, L.
    Rahim, T.
    Johnston, K.
    Harris, L.
    Thiry, A.
    Coric, V.
    L'Italien, G.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 181 - 182
  • [29] Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b/3 study
    Goadsby, P. J.
    Dodick, D. W.
    Ailani, J.
    Trugman, J. M.
    Finnegan, M.
    Lakkis, H.
    Lu, K.
    Szegedi, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 811 - 811
  • [30] Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study
    Goadsby, Peter J.
    Dodick, David W.
    Trugman, Joel M.
    Finnegan, Michelle
    Lakkis, Hassan
    Lu, Kaifeng
    Szegedi, Armin
    NEUROLOGY, 2019, 92 (15)
12345